• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » A Medtronic SVP leaves to become CFO of Caris Life Sciences

A Medtronic SVP leaves to become CFO of Caris Life Sciences

October 6, 2021 By Sean Whooley

Caris Life SciencesCaris Life Sciences announced today that it appointed former Medtronic (NYSE:MDT) executive Mike Weinstein as EVP & CFO.

Weinstein is a veteran of more than 25 years in finance and life sciences. He previously serveed as SVP of strategy at Medtronic and was a member of the medtech giant’s executive committee, where he oversaw global strategy for the organization. The Medtronic SVP role included providing counsel and input on business development, capital deployment and overall strategic direction for each of Medtronic’s businesses, according to a news release.

Before Medtronic, Weinstein was a managing director at JPMorgan Chase, leading the firm’s healthcare group within equity research.

“We are thrilled to welcome Mike to the Caris team,” Caris chairman & CEO David D. Halbert said in the release. “His passion for our mission, industry experience and strategic thinking will provide strong leadership as we position Caris for the next phase; expanding our offering to include both tissue and blood (measuring all coding genes) across hereditary and acquired variants, resulting in the most comprehensive offering ever.”

Irving, Texas–based Caris earlier this year announced an $830 million growth equity round at a $7.8 billion post-money valuation. The company develops molecular profiling offerings, including blood-based monitoring for patients before, during and after cancer treatment.

The company’s pan-cancer, circulating nucleic acids sequencing (cNAS) assay combines comprehensive molecular analysis and serial monitoring, making it what the company calls the “most powerful liquid biopsy assay ever developed.”

Caris also uses artificial intelligence (AI) and machine learning algorithms to better understand the molecular mechanisms of cancer to help identify and predict patient response to therapy.

“I am delighted to join Caris at such an exciting time,” Weinstein said. “In my 25-plus years, I’ve seen few companies with Caris’ potential to grow and to change the way we diagnose, monitor, treat and care for hundreds of thousands of cancer patients each year.”

Filed Under: Blood Management, Business/Financial News, Diagnostics, Featured, Genomics/Molecular Diagnostics, Oncology Tagged With: Caris Life Sciences, Personnel Moves

More recent news

  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy